Findings of Research Misconduct, 76703-76704 [2015-31057]

Download as PDF mstockstill on DSK4VPTVN1PROD with NOTICES Federal Register / Vol. 80, No. 237 / Thursday, December 10, 2015 / Notices Viral Hepatitis: Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis 2014–2016, details more than 150 actions to be undertaken between 2014 and 2016 by 20 federal agencies and offices from across the U.S. Departments of Health and Human Services (HHS), Housing and Urban Development (HUD), Justice (DOJ), and Veterans Affairs (VA). While the Viral Hepatitis Action Plan describes efforts to be undertaken by federal stakeholders, many of the successes our nation has seen in the fight against viral hepatitis have resulted from non-federal efforts including those of health departments, academic researchers, community-based organizations, professional organizations, education and advocacy groups, private industry, and other stakeholders. The Viral Hepatitis Action Plan provides a framework around which all stakeholders can engage to strengthen the nation’s response to viral hepatitis and envisions active involvement of and innovation by a broad mix of partners from both public and private sectors. The updated Action Plan describes four main goals to be achieved by 2020: • Increase in the proportion of persons who are aware of their hepatitis B virus (HBV) infection, from 33% to 66%. • Increase in the proportion of persons who are aware of their hepatitis C virus (HCV) infection, from 45% to 66%. • Reduce by 25% the number of new cases of HCV infection. • Eliminate mother-to-child transmission of HBV. This request for information seeks public comment on several key areas with respect to non-federal efforts undertaken throughout calendar years 2014–2015 that are consistent with the four main goals of the Viral Hepatitis Action Plan. Comments are sought on (but not limited to) the following: 1. Describe the type of organization or group with which you are affiliated (e.g., advocacy, private industry, health care, local, or state government, etc.). 2. What is the most significant need your community/clients experience with respect to combating viral hepatitis? 3. What activities conducted in 2014 and 2015 demonstrated the greatest advances toward reaching the goals of the Viral Hepatitis Action Plan? Responses are invited (but not limited to) viral hepatitis activities in the following areas: a. Raising awareness about viral hepatitis among the general public, specific targeted populations, and/or community leaders; VerDate Sep<11>2014 19:33 Dec 09, 2015 Jkt 238001 b. Training and/or increasing capacity of health care providers to prevent, diagnose, treat viral hepatitis; c. Developing strategies to promote timely viral hepatitis diagnosis and linkage to care; d. Developing/implementing clinical decision support tools and/or improved protocols in clinical settings that improve viral hepatitis health outcomes; e. Implementing strategies to educate women of child-bearing age and high risk groups about mother-to-infant transmission of hepatitis B; f. Reaching people who inject drugs with viral hepatitis information and services; g. Improving viral hepatitis infection prevention awareness and initiatives in medical settings; h. Developing strategies to foster stakeholder collaboration and sustainable programs; and i. Other (please specify). 4. Please include relevant information such as the dates of implementation; names of collaborating organizational partners; related Action Plan goal(s); geographic area and populations served, quantitative findings and outcomes such as number of tests done, proportion of positives identified; and links to online tools, resources, and publications. Please limit responses to four pages, single-sided, double spaced, 10 point font. Selected activities will be compiled and made available to federal partners, stakeholders, and the public in order to foster further expansion, innovation, and collaboration toward achieving the goals of the Viral Hepatitis Action Plan. Reponses to this RFI will also be used to inform future HHS strategic planning and implementation. 76703 report of an inquiry conducted by Virginia Commonwealth University (VCU), the willingness of the Respondent to settle this matter, and analysis conducted by ORI in its oversight review, ORI found that Dr. Girija Dasmahapatra, former Instructor, Department of Internal Medicine, VCU, engaged in research misconduct in research supported by National Cancer Institute (NCI), National Institutes of Health (NIH), grants R01 CA063753, R01 CA093738, and R01 CA100866. ORI found that false data were included in the following eleven (11) publications: • Blood 107:232–40, 2006 Jan (hereafter referred to as ‘‘Blood 2006’’) • Blood 115:4478–87, 2010 Jun 3 (hereafter referred to as ‘‘Blood 2010’’) • British Journal of Haematology 161:43–56, 2013 Apr (hereafter referred to as ‘‘BJH 2013’’) • Cancer Biology & Therapy 8:808–19, 2009 May (hereafter referred to as ‘‘CBT 2009’’) • Clinical Cancer Research 13:4280–90, 2007 Jul (hereafter referred to as ‘‘CCR 2007’’) • Leukemia 19:1579–89, 2005 Sep (hereafter referred to as ‘‘Leuk 2005’’) • Leukemia Research 30:1263–1272, 2006 (hereafter referred to as ‘‘LR 2006’’) • Molecular Cancer Therapeutics 10:1686–97, 2011 Sep (hereafter referred to as ‘‘MCT 2011’’) • Molecular Cancer Therapeutics 11:1122–32, 2012 May (hereafter referred to as ‘‘MCT 2012’’) • Molecular Cancer Therapeutics 13:2886–97, 2014 Dec (hereafter referred to as ‘‘MCT 2014’’) • Molecular Pharmacology 69:288–98, 2006 Jan (hereafter referred to as ‘‘MP Dated: December 7, 2015. 2006’’) Ronald O. Valdiserri, ORI found that Respondent falsified Deputy Assistant Secretary for Health, and/or fabricated data by reporting the Infectious Diseases, Office of the Assistant results of Western blot experiments and Secretary for Health. mouse imaging experiments that [FR Doc. 2015–31131 Filed 12–9–15; 8:45 am] examined interactions between multiple BILLING CODE 4150–28–P histone deacetylase and/or proteasome inhibitors in several cancer models. Specifically, Respondent duplicated, DEPARTMENT OF HEALTH AND reused, and/or relabeled Western blot HUMAN SERVICES panels and mouse images and claimed they represented different controls and/ Office of the Secretary or experimental results in: Findings of Research Misconduct • Blood 2006, Figures 2A and 2B (Tubulin), 2C (c-Jun & Tubulin), and AGENCY: Office of the Secretary, HHS. 3E and 3F (Tubulin) ACTION: Notice. • Blood 2010, Figures 4A and 4C (JNK & Tubulin) SUMMARY: Notice is hereby given that • BJH 2013, Figures 2A and 6B the Office of Research Integrity (ORI) (Tubulin) has taken final action in the following • CBT 2009, Figure 4B (Actin) case: • CCR 2007, Figures 3B (PARP) and 6A Girija Dasmahapatra, Ph.D., Virginia (Tubulin) Commonwealth University: Based on the PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 E:\FR\FM\10DEN1.SGM 10DEN1 76704 Federal Register / Vol. 80, No. 237 / Thursday, December 10, 2015 / Notices • Leuk 2005, Figures 3B (PARP CF) and 4A, 4B, and 4C (Tubulin) • LR 2006, Figure 3D (Actin—BaF/3– WT) • MCT 2011, Figures 2B and 3D (Tubulin) and 6B (0 d—CFZ–2.0mg/ Kg & 12 d—CFZ + VOR) • MCT 2012, Figures 3A (JNK & Tubulin, 3B (Tubulin—scram), 3D (Tubulin—pUSE–AKT cl.3), and 6B (CFZ + obato) • MCT 2014, Figures 3A (JNK 1 & Tubulin), 3B (JNK & Tubulin), and 3C (Tubulin) • MP 2006, Figures 1D and 1E (Caspase 3, CF Caspase 3, PARP & Tubulin), 2C (PARP), 3B, 4A, and 4B (Tubulin), 6A (Tubulin—U937–pSFFv 12 hr treatment & U937-Bcl-2-DN 24 hr treatment), and 9A (Cox-IV) Dr. Dasmahapatra has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed: (1) To exclude himself for a period of three (3) years from the effective date of the Agreement from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as ‘‘covered transactions’’ pursuant to HHS’ Implementation (2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the ‘‘Debarment Regulations’’); (2) To exclude himself from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for period of three (3) years, beginning on November 5, 2015; and (3) That the following publications will be retracted or corrected: Blood 2006, Blood 2010, BJH 2013, CBT 2009, CCR 2007, Leuk 2005, LR 2006, MCT 2011, MCT 2012, MCT 2014, and MP 2006. mstockstill on DSK4VPTVN1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200. Donald Wright, Acting Director, Office of Research Integrity. [FR Doc. 2015–31057 Filed 12–9–15; 8:45 am] BILLING CODE 4150–31–P VerDate Sep<11>2014 19:33 Dec 09, 2015 Jkt 238001 DEPARTMENT OF HOMELAND SECURITY United States Immigration and Customs Enforcement Agency Information Collection Activities: Comment Request; Extension of an Information Collection 30-Day notice of information collection for review; G–79A; information relating to beneficiary of Private Bill; OMB Control No. 1653– 0026. ACTION: The Department of Homeland Security, U.S. Immigration and Customs Enforcement (USICE), is submitting the following information collection request for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection is published in the Federal Register to obtain comments from the public and affected agencies. This information collection was previously published in the Federal Register on September 21, 2015, Vol. 80 No. 23491 allowing for a 60 day comment period. No comments were received on this information collection. The purpose of this notice is to allow an additional 30 days for public comments. Written comments and suggestions regarding items contained in this notice and especially with regard to the estimated public burden and associated response time should be directed to the Office of Information and Regulatory Affairs, Office of Management and Budget. Comments should be addressed to the OMB Desk Officer for U.S. Immigration and Customs Enforcement, Department of Homeland Security, and sent via electronic mail to oira_ submission@omb.eop.gov or faxed to (202) 395–5806. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information should address one or more of the following four points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Overview of This Information Collection (1) Type of Information Collection: Extension of a currently approved information collection (2) Title of the Form/Collection: Information Relating to Beneficiary of Private Bill. (3) Agency form number, if any, and the applicable component of the Department of Homeland Security sponsoring the collection: G–79A; U.S. Immigration and Customs Enforcement (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: State, Local, or Tribal Government. Section 404(b) of the Immigration and Nationality Act (8 U.S.C. 1101 note) provides for the reimbursement of States and localities for assistance provided in meeting an immigration emergency. This collection of information allows for State or local governments to request reimbursement. (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: 10 responses at 30 minutes (.50 hours) per response. (6) An estimate of the total public burden (in hours) associated with the collection: 300 annual burden hours. Dated: December 7, 2015. Scott Elmore, Program Manager, Forms Management Office, Office of the Chief Information Officer, U.S. Immigration and Customs Enforcement, Department of Homeland Security. [FR Doc. 2015–31108 Filed 12–9–15; 8:45 am] BILLING CODE 9111–28–P DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT [Docket No. FR–5835–N–28] 60-Day Notice of Proposed Information Collection: Multifamily Family SelfSufficiency (MF FSS) Program Escrow Credit Data Office of the Assistant Secretary for Housing—Federal Housing Commissioner, HUD. ACTION: Notice. AGENCY: HUD is seeking approval from the Office of Management and Budget (OMB) for the information collection described below. In accordance with the SUMMARY: E:\FR\FM\10DEN1.SGM 10DEN1

Agencies

[Federal Register Volume 80, Number 237 (Thursday, December 10, 2015)]
[Notices]
[Pages 76703-76704]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-31057]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Girija Dasmahapatra, Ph.D., Virginia Commonwealth University: Based 
on the report of an inquiry conducted by Virginia Commonwealth 
University (VCU), the willingness of the Respondent to settle this 
matter, and analysis conducted by ORI in its oversight review, ORI 
found that Dr. Girija Dasmahapatra, former Instructor, Department of 
Internal Medicine, VCU, engaged in research misconduct in research 
supported by National Cancer Institute (NCI), National Institutes of 
Health (NIH), grants R01 CA063753, R01 CA093738, and R01 CA100866.
    ORI found that false data were included in the following eleven 
(11) publications:

 Blood 107:232-40, 2006 Jan (hereafter referred to as ``Blood 
2006'')
 Blood 115:4478-87, 2010 Jun 3 (hereafter referred to as 
``Blood 2010'')
 British Journal of Haematology 161:43-56, 2013 Apr (hereafter 
referred to as ``BJH 2013'')
 Cancer Biology & Therapy 8:808-19, 2009 May (hereafter 
referred to as ``CBT 2009'')
 Clinical Cancer Research 13:4280-90, 2007 Jul (hereafter 
referred to as ``CCR 2007'')
 Leukemia 19:1579-89, 2005 Sep (hereafter referred to as ``Leuk 
2005'')
 Leukemia Research 30:1263-1272, 2006 (hereafter referred to as 
``LR 2006'')
 Molecular Cancer Therapeutics 10:1686-97, 2011 Sep (hereafter 
referred to as ``MCT 2011'')
 Molecular Cancer Therapeutics 11:1122-32, 2012 May (hereafter 
referred to as ``MCT 2012'')
 Molecular Cancer Therapeutics 13:2886-97, 2014 Dec (hereafter 
referred to as ``MCT 2014'')
 Molecular Pharmacology 69:288-98, 2006 Jan (hereafter referred 
to as ``MP 2006'')

    ORI found that Respondent falsified and/or fabricated data by 
reporting the results of Western blot experiments and mouse imaging 
experiments that examined interactions between multiple histone 
deacetylase and/or proteasome inhibitors in several cancer models. 
Specifically, Respondent duplicated, reused, and/or relabeled Western 
blot panels and mouse images and claimed they represented different 
controls and/or experimental results in:

 Blood 2006, Figures 2A and 2B (Tubulin), 2C (c-Jun & Tubulin), 
and 3E and 3F (Tubulin)
 Blood 2010, Figures 4A and 4C (JNK & Tubulin)
 BJH 2013, Figures 2A and 6B (Tubulin)
 CBT 2009, Figure 4B (Actin)
 CCR 2007, Figures 3B (PARP) and 6A (Tubulin)

[[Page 76704]]

 Leuk 2005, Figures 3B (PARP CF) and 4A, 4B, and 4C (Tubulin)
 LR 2006, Figure 3D (Actin--BaF/3-WT)
 MCT 2011, Figures 2B and 3D (Tubulin) and 6B (0 d--CFZ-2.0mg/
Kg & 12 d--CFZ + VOR)
 MCT 2012, Figures 3A (JNK & Tubulin, 3B (Tubulin--scram), 3D 
(Tubulin--pUSE-AKT cl.3), and 6B (CFZ + obato)
 MCT 2014, Figures 3A (JNK 1 & Tubulin), 3B (JNK & Tubulin), 
and 3C (Tubulin)
 MP 2006, Figures 1D and 1E (Caspase 3, CF Caspase 3, PARP & 
Tubulin), 2C (PARP), 3B, 4A, and 4B (Tubulin), 6A (Tubulin--U937-pSFFv 
12 hr treatment & U937-Bcl-2-[Delta]N 24 hr treatment), and 9A (Cox-IV)

    Dr. Dasmahapatra has entered into a Voluntary Exclusion Agreement 
(Agreement) and has voluntarily agreed:
    (1) To exclude himself for a period of three (3) years from the 
effective date of the Agreement from any contracting or subcontracting 
with any agency of the United States Government and from eligibility or 
involvement in nonprocurement programs of the United States Government 
referred to as ``covered transactions'' pursuant to HHS' Implementation 
(2 CFR part 376 et seq) of OMB Guidelines to Agencies on Governmentwide 
Debarment and Suspension, 2 CFR part 180 (collectively the ``Debarment 
Regulations'');
    (2) To exclude himself from serving in any advisory capacity to PHS 
including, but not limited to, service on any PHS advisory committee, 
board, and/or peer review committee, or as a consultant for period of 
three (3) years, beginning on November 5, 2015; and
    (3) That the following publications will be retracted or corrected: 
Blood 2006, Blood 2010, BJH 2013, CBT 2009, CCR 2007, Leuk 2005, LR 
2006, MCT 2011, MCT 2012, MCT 2014, and MP 2006.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of 
Investigative Oversight, Office of Research Integrity, 1101 Wootton 
Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.

Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2015-31057 Filed 12-9-15; 8:45 am]
 BILLING CODE 4150-31-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.